NASDAQ:ORMP - Oramed Pharmaceuticals Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$3.41 -0.02 (-0.58 %)
(As of 01/18/2019 04:00 PM ET)
Previous Close$3.41
Today's Range$3.35 - $3.50
52-Week Range$2.97 - $8.98
Volume15,634 shs
Average Volume37,335 shs
Market Capitalization$59.61 million
P/E Ratio-3.97
Dividend YieldN/A
Beta0.58
Oramed Pharmaceuticals Inc. engages in the research and development of pharmaceutical solutions for the use of orally ingestible capsules or pills for delivery of polypeptides. Its product portfolio includes ORMD-0801, an oral insulin capsule for the treatment of diabetes; and ORMD-0901, an oral glucagon-like peptide-1 analog capsule for the treatment of type 2 diabetes. It is also developing a weight loss treatment in the form of an oral leptin capsule. The company was formerly known as Integrated Security Technologies, Inc. and changed its name to Oramed Pharmaceuticals Inc. in April 2006. Oramed Pharmaceuticals Inc. was founded in 2002 and is based in New York, New York.

Receive ORMP News and Ratings via Email

Sign-up to receive the latest news and ratings for ORMP and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:ORMP
CUSIPN/A
Phone646-844-1164

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$2.45 million
Book Value$1.66 per share

Profitability

Net Income$-12,720,000.00
Net Margins-577.99%

Miscellaneous

Employees13
Market Cap$59.61 million
OptionableOptionable

Oramed Pharmaceuticals (NASDAQ:ORMP) Frequently Asked Questions

What is Oramed Pharmaceuticals' stock symbol?

Oramed Pharmaceuticals trades on the NASDAQ under the ticker symbol "ORMP."

How were Oramed Pharmaceuticals' earnings last quarter?

Oramed Pharmaceuticals, Inc. (NASDAQ:ORMP) posted its earnings results on Wednesday, November, 28th. The biotechnology company reported ($0.18) EPS for the quarter, topping the Thomson Reuters' consensus estimate of ($0.28) by $0.10. The biotechnology company earned $0.62 million during the quarter. Oramed Pharmaceuticals had a negative return on equity of 59.72% and a negative net margin of 577.99%. View Oramed Pharmaceuticals' Earnings History.

When is Oramed Pharmaceuticals' next earnings date?

Oramed Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Thursday, January 24th 2019. View Earnings Estimates for Oramed Pharmaceuticals.

What price target have analysts set for ORMP?

2 equities research analysts have issued twelve-month price objectives for Oramed Pharmaceuticals' shares. Their predictions range from $25.00 to $25.00. On average, they anticipate Oramed Pharmaceuticals' share price to reach $25.00 in the next year. This suggests a possible upside of 633.1% from the stock's current price. View Analyst Price Targets for Oramed Pharmaceuticals.

What is the consensus analysts' recommendation for Oramed Pharmaceuticals?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Oramed Pharmaceuticals in the last year. There are currently 1 hold rating and 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Oramed Pharmaceuticals.

Has Oramed Pharmaceuticals been receiving favorable news coverage?

News articles about ORMP stock have trended somewhat positive this week, according to InfoTrie Sentiment Analysis. The research group ranks the sentiment of press coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Oramed Pharmaceuticals earned a news sentiment score of 0.9 on InfoTrie's scale. They also assigned media stories about the biotechnology company a news buzz of 2.0 out of 10, meaning that recent press coverage is very unlikely to have an effect on the company's share price in the next several days.

Who are some of Oramed Pharmaceuticals' key competitors?

Who are Oramed Pharmaceuticals' key executives?

Oramed Pharmaceuticals' management team includes the folowing people:
  • Mr. Nadav Kidron, CEO, Pres & Exec. Director (Age 44)
  • Dr. Miriam Kidron, Chief Scientific Officer, Chief Medical & Technology Officer and Director (Age 78)
  • Ms. Hilla Eisenberg CPA, CFO, Treasurer & Sec. (Age 34)
  • Dr. Roy Eldor M.D., Ph.D., Chief Medical Advisor & Member of the Scientific Advisory Board
  • Dr. Ronald Law, Chief Strategy Officer (Age 65)

How do I buy shares of Oramed Pharmaceuticals?

Shares of ORMP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Oramed Pharmaceuticals' stock price today?

One share of ORMP stock can currently be purchased for approximately $3.41.

How big of a company is Oramed Pharmaceuticals?

Oramed Pharmaceuticals has a market capitalization of $59.61 million and generates $2.45 million in revenue each year. The biotechnology company earns $-12,720,000.00 in net income (profit) each year or ($0.86) on an earnings per share basis. Oramed Pharmaceuticals employs 13 workers across the globe.

What is Oramed Pharmaceuticals' official website?

The official website for Oramed Pharmaceuticals is http://www.oramed.com.

How can I contact Oramed Pharmaceuticals?

Oramed Pharmaceuticals' mailing address is 142 W. 57TH STREET 11TH FLOOR, NEW YORK NY, 10019. The biotechnology company can be reached via phone at 646-844-1164 or via email at [email protected]


MarketBeat Community Rating for Oramed Pharmaceuticals (NASDAQ ORMP)

Community Ranking:  3.2 out of 5 (star star star)
Outperform Votes:  217 (Vote Outperform)
Underperform Votes:  121 (Vote Underperform)
Total Votes:  338
MarketBeat's community ratings are surveys of what our community members think about Oramed Pharmaceuticals and other stocks. Vote "Outperform" if you believe ORMP will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ORMP will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 1/19/2019 by MarketBeat.com Staff

Featured Article: Stop Order

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel